ReviewPathogens (Basel, Switzerland)2023
Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.
Review in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 55 citations in OpenAlex.
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Differential Signature of Gut Microbiota in Female Patients with Condyloma Acuminatum and Its Association with Persistent Human Papillomavirus Infection.Journal of clinical medicine · 2026Article
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
- Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.International journal of molecular sciences · 2026Article
- Human papillomavirus 18 E6-specific Affibody inhibits cervical cancer cell proliferation and induces apoptosis.Applied microbiology and biotechnology · 2026Article
- Prevalence and genotypic distribution of high-risk human papillomavirus in primary breast tumors in Western Uganda: a case-control study.Scientific reports · 2026Article
- Cell-Mediated Immunity Against Human Papillomavirus Infection: From Viral Clearance to Oncogenesis.Viruses · 2026Review
- LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8Cellular and molecular life sciences : CMLS · 2026Article
- Disruption of EMT Signaling and Migration by Moringa oleifera Leaf Powder-Silver Nanoparticles (MOLP-AgNPs) in HeLa Cervical Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- The Relationship Between Body Mass Index and Cervical High-Risk HPV Positivity in Women: A Single-Center Study.Microorganisms · 2026Article
- Human papillomavirus prevalence and genotypic characteristics among men in Wuhan, China: a cross-sectional study.BMC infectious diseases · 2026Article
- Integrative metabolomic and single-cell transcriptomic analysis of recurrent condyloma acuminatum in humans.Scientific reports · 2026Article
- Dynamics of Cervical Lesions After Excisional Treatment in Relation to HPV Genotypes and Cytological Findings.Journal of clinical medicine · 2026Article
- Efficacy of immune checkpoint inhibitors plus chemotherapy versus chemotherapy-based control in cervical cancer: a meta-analysis.American journal of cancer research · 2026Review
- Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncology research · 2026Review
- Economic burden of human papillomavirus-related cancers in New Zealand.BMJ public health · 2026Article
- Cervical cancer: Riverside women's knowledge in the Brazilian Amazon about preventive measures.PloS one · 2026Article
- CCL20 secreted by KRT15Cell death & disease · 2025Article
- HPV-driven inflammatory pathways in ovarian carcinogenesis: molecular mechanisms and emerging therapeutic interventions.Journal of ovarian research · 2025Review
- Human Papillomavirus: An Old New History.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is implicated in over 90% of cervical cancer cases, with factors like regional variability, HPV genotype, the population studied, HPV vaccination status, and anatomical sample collection location influencing the prevalence and pathology of HPV-induced cancer. HPV-16 and -18 are mainly responsible for the progression of several cancers, including cervix, anus, vagina, penis, vulva, and oropharynx. The oncogenic ability of HPV is not only sufficient for the progression of malignancy, but also for other tumor-generating steps required for the production of invasive cancer, such as coinfection with other viruses, lifestyle factors such as high parity, smoking, tobacco chewing, use of contraceptives for a long time, and immune responses such as stimulation of chronic stromal inflammation and immune deviation in the tumor microenvironment. Viral evasion from immunosurveillance also supports viral persistence, and virus-like particle-based prophylactic vaccines have been licensed, which are effective against high-risk HPV types. In addition, vaccination awareness programs and preventive strategies could help reduce the rate and incidence of HPV infection. In this review, we emphasize HPV infection and its role in cancer progression, molecular and immunopathogenesis, host immune response, immune evasion by HPV, vaccination, and preventive schemes battling HPV infection and HPV-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.